Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia

Hepatitis B virus (HBV) reactivation is an increasingly recognized cause of morbidity and mortality in patients undergoing chemotherapy. In haematology, the risk of reactivation of B hepatitis among HBsAg-positive patients has been documented; therefore, use of lamivudine prophylaxis is recommended...

Descripción completa

Detalles Bibliográficos
Autores principales: Toscanini, Federica, De Leo, Pasqualina, Calcagno, Giuseppe, Malfatti, Federica, Grasso, Alessandro, Anselmo, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411891/
https://www.ncbi.nlm.nih.gov/pubmed/25954538
http://dx.doi.org/10.1155/2011/258791

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4411891/
https://www.ncbi.nlm.nih.gov/pubmed/25954538
http://dx.doi.org/10.1155/2011/258791

Ejemplares similares